Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 50

Sort by

Sort Order Select

Journal Articles

Clinical Efficacy of Intracellular Molecular Inhibitors for Relapsed, Refractory Multiple Myeloma: A Systematic Review of Early Clinical Data

Shehroz Aslam, MD, Mustafa Nadeem Malik, MD, Abdul Rafae, MD, Rida Riaz, MBBS, Muhammad Jahanzeb Khalil, MD, Faisal Mahfooz, MD, Madeeha Shafqat, Anum Qureshi, Insija Ilyas Selene, MBBS, Syed Shabee Hassan, MD, Muhammad Junaid Tariq, MD, Muhammad Yasir, MD, Sharoon Samuel, MBBS, Maryam Sadiq, MBBS, Faiz Anwer, MD

Blood (2018) 132 (Supplement 1): 1950.

https://doi.org/10.1182/blood-2018-99-111587

Published: 2018

Journal Articles

Defining the Most Effective Proteasome Inhibition in Multiple Myeloma: Head-to-Head Comparison of Currently Available Proteasome Inhibitors

Andrej Besse, Lenka Besse, Marianne Kraus, Juergen Bader, Gerjan de Bruin, Herman S Overkleeft, Christoph Driessen, MD

Blood (2017) 130 (Supplement 1): 5388.

https://doi.org/10.1182/blood.V130.Suppl_1.5388.5388

Published: 2017

Journal Articles

Rethinking Risk-Benefit Assessment for Phase I Multiple Myeloma Trials

Ehsan Malek, MD, Caner Saygin, MD, Rebecca Ye, Byung-gyu Kim, DVM, Fahrettin Covut, MD, Marcos De Lima, MD, James J. Driscoll, MD PhD

Blood (2016) 128 (22): 1146.

https://doi.org/10.1182/blood.V128.22.1146.1146

Published: 2016

Journal Articles

Pmd-107: Marizomib, Pomalidomide and Low Dose-Dexamethasone Combination Study in Relapsed/Refractory Multiple Myeloma (NCT02103335): Full Enrollment Results from a Phase-1 Multicenter, Open Label Study

Andrew Spencer, Simon Harrison, MBBS MRCP(UK) FRCPath(UK) FRACP PhD, Jacob P. Laubach, MD, Jeffrey Zonder, MD, Ashraf Z Badros, MD, Krystal Bergin, Amit Khot, MD, Todd Zimmerman, MD, Kenneth C. Anderson, MD, Ann MacLaren, PhD, Steven D Reich, MD, Mohit Trikha, PhD, Paul G. Richardson, MD

Blood (2016) 128 (22): 3326.

https://doi.org/10.1182/blood.V128.22.3326.3326

Published: 2016

Journal Articles

TOP2A a New Predictive Marker of Response to Carfilzomib in Multiple Myeloma

Antonia Reale, MD Oncologist in training, Tiffany Khong, BSc, PhD, Sridurga Mithraprabhu, PhD, John Reynolds, Malarmathy Ramachandran, Ioanna Savvidou, MD PhD, Krystal Bergin, Jay Hocking, MD PhDstudent, Andrew Spencer

Blood (2016) 128 (22): 4461.

https://doi.org/10.1182/blood.V128.22.4461.4461

Published: 2016

Journal Articles

Marizomib for CNS-Multiple Myeloma

Ashraf Z Badros, MD, Zeba Singh, MD, Binod Dhakal, MDMS, Young Kwok, MD, Ann MacLaren, PhD, Paul G. Richardson, MD, Mohit Trikha, PhD, Hari Parameswaran, MD

Blood (2016) 128 (22): 2118.

https://doi.org/10.1182/blood.V128.22.2118.2118

Published: 2016

Journal Articles

Phase 1 study of marizomib in relapsed or relapsed and refractory multiple myeloma: NPI-0052-101 Part 1

Paul G. Richardson, Todd M. Zimmerman, Craig C. Hofmeister, Moshe Talpaz, Asher A. Chanan-Khan, Jonathan L. Kaufman, Jacob P. Laubach, Dharminder Chauhan, Andrzej J. Jakubowiak, Steven Reich, Mohit Trikha, Kenneth C. Anderson

Blood (2016) 127 (22): 2693–2700.

https://doi.org/10.1182/blood-2015-12-686378

Published: 2016

Journal Articles

Defibrotide for the Treatment of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome with Multi-Organ Dysfunction: Final Results from a Pivotal, Historically Controlled, Phase 3 Trial

Blood (2015) 126 (23): 737.

https://doi.org/10.1182/blood.V126.23.737.737

Published: 2015

Journal Articles

Phase 1, Multicenter, Open-Label, Combination Study (NPI-0052-107; NCT02103335) of Pomalidomide (POM), Marizomib (MRZ, NPI-0052), and Low-Dose Dexamethasone (LD-DEX) in Patients with Relapsed and Refractory Multiple Myeloma

Andrew Spencer, Jacob P. Laubach, MD, Jeffrey A Zonder, MD, Ashraf Z Badros, MD, Simon Harrison, MD, Amit Khot, MD, Dharminder Chauhan, PhD, Kenneth C. Anderson, MD, Steven D Reich, MD, Mohit Trikha, PhD, Paul G. Richardson, MD

Blood (2015) 126 (23): 4220.

https://doi.org/10.1182/blood.V126.23.4220.4220

Published: 2015

Journal Articles

In Vitro and In Vivo Efficacy of a Novel Orally Bioavailable Beta-Catenin Inhibitor-BC2059- As Monotherapy or in Combination with Proteasome Inhibitors in Multiple Myeloma

Ioanna Savvidou, MD PhDstudent, Tiffany T. Khong, PhD, Stephen K. Horrigan, PhD, Andrew Spencer

Blood (2015) 126 (23): 1816.

https://doi.org/10.1182/blood.V126.23.1816.1816

Published: 2015

Journal Articles

Oral Proteasome Inhibitor Marizomib and IMiD® Imunomodulatory Drug Pomalidomide Trigger Synergistic Anti-Myeloma Activity and Enhanced Proteasome Inhibition in Vitro and In Vivo

Deepika Sharma Das, PhD, Arghya Ray, PhD, Yan Song, PhD, Paul Richardson, MD, Mohit Trikha, PhD, Dharminder Chauhan, PhD, Kenneth C Anderson, MD

Blood (2015) 126 (23): 1821.

https://doi.org/10.1182/blood.V126.23.1821.1821

Published: 2015

Journal Articles

Marizomib Overcomes Compensatory Hyperactivation of Trypsin-like and Caspase-like Subunits to Provide Pan-Proteasome Subunit Inhibition in Patients with Multiple Myeloma and Solid Tumors

Andrew Spencer, Simon Harrison, MD, Francis Burrows, Paul Mainwaring, MD, Timothy Price, MD, Michael J Millward, MD, Peeter Padrik, MD, Craig Underhill, MD, Paul Cannell, MD, Steven D Reich, MD, Mohit Trikha, PhD

Blood (2015) 126 (23): 5375.

https://doi.org/10.1182/blood.V126.23.5375.5375

Published: 2015

Journal Articles

Marcks Marks Resistance to Proteasome Inhibitors: Exocytosis of Polyubiquitinated Proteins in Bortezomib-Resistant Leukemia Cells

Niels Franke, MD, Gertjan J.L. Kaspers, MD PhD, Yehuda G Assaraf, PhD, Johan Van Meerloo, MSc, Denise Niewerth, PhD, Terzah M. Horton, MD PhD, Wee Joo Chng, MD PhD, Chonglei Bi, B.S, Rene X. Menezes, PhD, Renée J. Musters, PhD, Pino J. Poddighe, PhD, Floortje Kessler, Serge Smeets, PhD, Bauke Ylstra, PhD, Sonja Zweegman, MD PhD, Gerrit Jansen, PhD, Jacqueline Cloos, PhD

Blood (2015) 126 (23): 3712.

https://doi.org/10.1182/blood.V126.23.3712.3712

Published: 2015

Journal Articles

Synergistic Anti-Myeloma Activity of a Proteasome Inhibitor Marizomib and IMiD® Immunomodulatory Drug Pomalidomide

Deepika Sharma Das, PhD, Durgadevi Ravillah, PhD, Arghya Ray, Yan Song, PhD, Paul G. Richardson, Mohit Trikha, PhD, Dharminder Chauhan, PhD, Kenneth C. Anderson, MD

Blood (2014) 124 (21): 2099.

https://doi.org/10.1182/blood.V124.21.2099.2099

Published: 2014

Journal Articles

Unique Apoptotic Effects Of Panobinostat and Marizomib In Acute Myeloid Leukemia and Bortezomib-Resistant Models

Fernando F. Corrales-Medina, M.D., Daniela E. Egas Bejar, M.D., Christa Manton, B.S., Blake Johnson, M.S., Mary E Irwin, Ph.D., Robert Z. Orlowski, M.D., Ph.D., Joya Chandra, Ph.D.

Blood (2013) 122 (21): 3837.

https://doi.org/10.1182/blood.V122.21.3837.3837

Published: 2013

Journal Articles

Activity of Single Agent Drugs in Phase I and II Trials Best Predicts Future Clinical Utility in Multiple Myeloma

Klaus Martin Kortuem, MD, Steven R Schuster, MD, Meaghan L. Khan, MD, Kaitlyn E. Zidich, Victor H Jimenez-Zepeda, MD, Rafael Fonseca, MD, Keith Stewart, MBA, MB, CHB

Blood (2012) 120 (21): 4034.

https://doi.org/10.1182/blood.V120.21.4034.4034

Published: 2012

Journal Articles

Phase 1 Clinical Evaluation of Twice-Weekly Marizomib (NPI-0052), a Novel Proteasome Inhibitor, in Patients with Relapsed/Refractory Multiple Myeloma (MM)

Paul G. Richardson, MD, Andrew Spencer, MD, Paul Cannell, MBBS, FRCPA, FRACP, Simon J. Harrison, MBBS MRCP (uk) MRCPath (uk) PhD, Laurence Catley, MBBS, FRCPA, FRACP, Craig Underhill, MBBS, FRACP, Todd M. Zimmerman, MD, Craig C. Hofmeister, MD, Andrzej J Jakubowiak, MD, PhD, Jacob P. Laubach, MD, Michael A. Palladino, PhD, Angie M. Longenecker, RN, BSN, Ana Lay, Sandra Wear, RN, G. Kenneth Lloyd, PhD, Alison L. Hannah, MD, Steve Reich, MD, Matthew A. Spear, MD, Kenneth C. Anderson, MD

Blood (2011) 118 (21): 302.

https://doi.org/10.1182/blood.V118.21.302.302

Published: 2011

Journal Articles

Combination of novel proteasome inhibitor NPI-0052 and lenalidomide trigger in vitro and in vivo synergistic cytotoxicity in multiple myeloma

Dharminder Chauhan, Ajita V. Singh, Bryan Ciccarelli, Paul G. Richardson, Michael A. Palladino, Kenneth C. Anderson

Blood (2010) 115 (4): 834–845.

https://doi.org/10.1182/blood-2009-03-213009

Published: 2010

Includes: Supplemental data

Journal Articles

Inhibition of the RKIP and PTEN-Transcription Repressor Snail in B-NHL by the Proteasome Inhibitor NPI-0052: Roles of RKIP and PTEN Induction in the Reversal of Resistance to TRAIL Apoptosis.

Stavroula Baritaki, Kam Yeung, Ph.D., Katherine Wu, Haiming Chen, MD, PhD, James R. Berenson, MD, Michael A. Palladino, PhD, Benjamin Bonavida, PhD

Blood (2009) 114 (22): 3938.

https://doi.org/10.1182/blood.V114.22.3938.3938

Published: 2009

Journal Articles

Phase 1 Clinical Trial of the Novel Structure Proteasome Inhibitor NPI-0052 in Patients with Relapsed and Relapsed/Refractory Multiple Myeloma (MM).

Paul Richardson, M.D, Craig Hofmeister, MD, Andrzej Jakubowiak, MD, PhD, Todd M. Zimmerman, MD, Matthew A. Spear, MD, Michael A. Palladino, PhD, Angie M. Longenecker, RN, BSN, Susan L. Kelly, MD, Saskia Neuteboom, PhD, Gillian F Cropp, MSc, G. Kenneth Lloyd, PhD, Alison L. Hannah, MD, Kenneth C. Anderson, MD

Blood (2009) 114 (22): 431.

https://doi.org/10.1182/blood.V114.22.431.431

Published: 2009

NARROW

Clinical Efficacy of Intracellular Molecular Inhibitors for Relapsed, Refractory Multiple Myeloma: A Systematic Review of Early Clinical Data

Defining the Most Effective Proteasome Inhibition in Multiple Myeloma: Head-to-Head Comparison of Currently Available Proteasome Inhibitors

Rethinking Risk-Benefit Assessment for Phase I Multiple Myeloma Trials

Pmd-107: Marizomib, Pomalidomide and Low Dose-Dexamethasone Combination Study in Relapsed/Refractory Multiple Myeloma (NCT02103335): Full Enrollment Results from a Phase-1 Multicenter, Open Label Study

TOP2A a New Predictive Marker of Response to Carfilzomib in Multiple Myeloma

Marizomib for CNS-Multiple Myeloma

Phase 1 study of marizomib in relapsed or relapsed and refractory multiple myeloma: NPI-0052-101 Part 1

Defibrotide for the Treatment of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome with Multi-Organ Dysfunction: Final Results from a Pivotal, Historically Controlled, Phase 3 Trial

Phase 1, Multicenter, Open-Label, Combination Study (NPI-0052-107; NCT02103335) of Pomalidomide (POM), Marizomib (MRZ, NPI-0052), and Low-Dose Dexamethasone (LD-DEX) in Patients with Relapsed and Refractory Multiple Myeloma

In Vitro and In Vivo Efficacy of a Novel Orally Bioavailable Beta-Catenin Inhibitor-BC2059- As Monotherapy or in Combination with Proteasome Inhibitors in Multiple Myeloma

Oral Proteasome Inhibitor Marizomib and IMiD® Imunomodulatory Drug Pomalidomide Trigger Synergistic Anti-Myeloma Activity and Enhanced Proteasome Inhibition in Vitro and In Vivo

Marizomib Overcomes Compensatory Hyperactivation of Trypsin-like and Caspase-like Subunits to Provide Pan-Proteasome Subunit Inhibition in Patients with Multiple Myeloma and Solid Tumors

Marcks Marks Resistance to Proteasome Inhibitors: Exocytosis of Polyubiquitinated Proteins in Bortezomib-Resistant Leukemia Cells

Synergistic Anti-Myeloma Activity of a Proteasome Inhibitor Marizomib and IMiD® Immunomodulatory Drug Pomalidomide

Unique Apoptotic Effects Of Panobinostat and Marizomib In Acute Myeloid Leukemia and Bortezomib-Resistant Models

Activity of Single Agent Drugs in Phase I and II Trials Best Predicts Future Clinical Utility in Multiple Myeloma

Phase 1 Clinical Evaluation of Twice-Weekly Marizomib (NPI-0052), a Novel Proteasome Inhibitor, in Patients with Relapsed/Refractory Multiple Myeloma (MM)

Combination of novel proteasome inhibitor NPI-0052 and lenalidomide trigger in vitro and in vivo synergistic cytotoxicity in multiple myeloma

Inhibition of the RKIP and PTEN-Transcription Repressor Snail in B-NHL by the Proteasome Inhibitor NPI-0052: Roles of RKIP and PTEN Induction in the Reversal of Resistance to TRAIL Apoptosis.

Phase 1 Clinical Trial of the Novel Structure Proteasome Inhibitor NPI-0052 in Patients with Relapsed and Relapsed/Refractory Multiple Myeloma (MM).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only